Statement of due diligence assessments according to the Openness Act
In order to deal with actual and potential negative consequences for basic human rights and decent working conditions, the company has previously established procedures for notification, complaints and conflict management. In addition, we have established a procedure for ongoing supplier evaluation so that from 2023 new suppliers must answer our survey before they are assessed as a supplier. A Code of Conduct has also been adopted, which describes the company's ethical guidelines, as well as a procedure that describes work methodology for due diligence assessment.
In 2023, FDA AS has carried out due diligence assessments by;
- direct a survey to our suppliers. A representative number of 30 companies answered the survey.
- Subsequently, the administration and general manager have carried out risk assessments based on answers from the survey.
- In addition, we have made assessments based on our knowledge of all our suppliers.
We have also evaluated our own operations, focusing on any existing and potential negative consequences of the company's operations. Based on materiality assessments, we have seen no need for extraordinary measures other than that we will specify for both new and existing suppliers that they must respond to our supplier survey/inquiries regarding due diligence assessments in order to be assessed as a supplier.
Furthermore, we shall continue the work of continuous improvement in our operations, and by following and further developing our guidelines and procedures in the quality system, continue to focus on the purposes of the Transparency Act.
